Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

Université de Montréal

$105,000.00

Allostatic load as a predictor of pharmacological treatment response in patients with major depressive disorder

EF 2020-21

Résumé
According to the World Health Organization, depression is a leading cause of disability worldwide. Approximately 15% of people will experience depression at some point in their life. Less than half of people diagnosed with depression respond to current treatments, including antidepressant medication. Future research must better understand factors that predispose individuals to depression, but also be able to find ways to predict who will respond to antidepressant medication or not. One reason that could explain poor antidepressant treatment response rates is the popular belief that depression is a 'disease of the mind'. This has shaped how we screen/diagnose depression in clinical practice - that is, by assessing the presence of at least 5 of 9 symptoms of depression listed in a diagnostic manual in a standardized interview. As such, two patients could receive a same depression diagnosis, while only sharing one symptom. Importantly, this suggests that distinct types of depression exist, that may in turn respond differently to a similar antidepressant treatment. Contrary to popular beliefs, depression is a 'full-body disease' that emerges from complex interactions of repeated exposure to stressful life events, like unemployment or divorce, along with biological factors that increase a person's risk of developing depression. As such, research must identify markers of biological functioning that will help predict health trajectories and treatment responses. Our project aims to measure biological markers of allostatic load - a comprehensive measure of biological wear and tear that chronic stress exerts on hormonal, immune, cardiovascular and metabolic systems - in a large sample of patients who have consulted psychiatric emergency services, and were seen again 1 month later at an outpatient clinic. This will allow us to measure how multiple markers of biological functioning can help predict antidepressant treatment responses and help guide novel drug discoveries.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
439835
Name
Beauchamp-Kerr Philippe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Allostatic load as a predictor of pharmacological treatment response in patients with major depressive disorder
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Allostatic Load; Antidepressant Treatment; Biological Psychiatry; Chronic Stress; Major Depressive Disorder; Transdiagnostical Approaches
Abstract
According to the World Health Organization, depression is a leading cause of disability worldwide. Approximately 15% of people will experience depression at some point in their life. Less than half of people diagnosed with depression respond to current treatments, including antidepressant medication. Future research must better understand factors that predispose individuals to depression, but also be able to find ways to predict who will respond to antidepressant medication or not. One reason that could explain poor antidepressant treatment response rates is the popular belief that depression is a 'disease of the mind'. This has shaped how we screen/diagnose depression in clinical practice - that is, by assessing the presence of at least 5 of 9 symptoms of depression listed in a diagnostic manual in a standardized interview. As such, two patients could receive a same depression diagnosis, while only sharing one symptom. Importantly, this suggests that distinct types of depression exist, that may in turn respond differently to a similar antidepressant treatment. Contrary to popular beliefs, depression is a 'full-body disease' that emerges from complex interactions of repeated exposure to stressful life events, like unemployment or divorce, along with biological factors that increase a person's risk of developing depression. As such, research must identify markers of biological functioning that will help predict health trajectories and treatment responses. Our project aims to measure biological markers of allostatic load - a comprehensive measure of biological wear and tear that chronic stress exerts on hormonal, immune, cardiovascular and metabolic systems - in a large sample of patients who have consulted psychiatric emergency services, and were seen again 1 month later at an outpatient clinic. This will allow us to measure how multiple markers of biological functioning can help predict antidepressant treatment responses and help guide novel drug discoveries.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Beauchamp-Kerr, Philippe
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~